Loading...
Staphylococcus aureus bacteremia (SaB) is a heterogenous condition with varying degrees of morbidity and mortality. As such, a “one size fit all” therapeutic approach is likely to overtreat some patients but undertreat others. Risk factors for mortality, relapse, and other adverse outcomes include endocarditis, osteomyelitis, and the presence of biomedical devices. Researchers retrospectively analyzed prospectively collected data from 578 patients with high-risk SaB, of whom 313 (54%) received combination therapy. Of the combination-therapy patients, 242 received combination therapy that included rifampicin and 58 that included fosfomycin. The patients were participants in the INSTINCT (invasive S. aureus infections cohort) study at two lar…